Towards improved respiratory outcomes in preterm infants through rapid and effective aerosalisation of medication to the lung

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Babies born premature are greatest at risk from increasingly common respiratory illnesses. It is possible that delivering a medication by aerosol will be the most effective method of treatment. For premature babies that need breathing support, inhaled medication could improve care. For highly infectious respiratory illnesses such as RSV, with no vaccines available, we need to protect babies very early in life. I will use an established lamb model to test fast medication delivery to the lungs.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Early Career Fellowships

Funding Amount: $318,768.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Paediatrics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

infant | premature birth | respiratory syncytial virus | surfactant | vaccination